MLV Comments On TG Therapeutics Following Discussions With Management

Before the market opened today, MLV analyst Arlinda Lee reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, which implies an upside of 57% from current levels.

Lee wrote, “Following discussions with Management, we believe the Phase 3 GENUINE trial of TG-1101 + ibrutinib in high-risk chronic lymphocytic leukemia (CLL) has started recruiting and that at least one pivotal trial of combination of TG-1101 + TGR-1202 will commence in 2015. Given the efficacy and safety seen in Phase 1 trials, we think this is an astute move, and TGTX’s ability to combine its PI3K-delta inhibitor and anti-CD20 antibody in-house puts them in an enviable position from a marketing and pricing perspective.”

Furthermore, the analyst highlighted the upcoming milestones¬†for the stock, “In 1H15, we expect initiation of the first Phase 3 trial of the 1303 combination and completion of enrollment for the ongoing TG-1101 + lenalidomide trial. In 2H15, we anticipate initiation of a second Phase 3 1303 trial, a second Phase 1 trial of a triple combination including ublituximab and TGR-1202 and Phase 1 TGR-1202 + brentuximab results in r/r NHL and TGR-1202 with obinutuzumab and chlorambucil results in CLL. We also expect IRAK-4 inhibitors to enter the clinic and initiation of TGR-1202 trials in autoimmune disease.”

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts